JNJ-88549968 for Myeloproliferative Disorder
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new drug, JNJ-88549968, to find the safest and most effective dose for patients. It aims to determine the best dosing schedule and ensure the drug's safety.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
What makes the drug JNJ-88549968 unique for treating myeloproliferative disorders?
JNJ-88549968 is likely a novel JAK2 inhibitor, targeting the JAK2-STAT pathway, which is crucial in myeloproliferative disorders. This drug may offer a new approach by specifically inhibiting the JAK2V617F mutation, a common driver in these conditions, potentially providing a more targeted treatment option compared to existing JAK inhibitors.12345
What data supports the effectiveness of the drug JNJ-88549968 for treating myeloproliferative disorders?
Who Is on the Research Team?
Janssen Research & Development, LLC Clinical Trial
Principal Investigator
Janssen Research & Development, LLC
Are You a Good Fit for This Trial?
This trial is for adults with a specific mutation called CALR in their blood cells, leading to conditions like thrombocytosis and myelofibrosis. They should be able to perform daily activities with ease or only have slight limitations (ECOG <=2). The study excludes details not provided.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive JNJ-88549968 with dose escalation to determine the recommended phase 2 dose (RP2D) and optimal dosing schedule based on safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy
Dose Expansion
Participants receive JNJ-88549968 at the RP2D regimen determined in dose escalation
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- JNJ-88549968
Find a Clinic Near You
Who Is Running the Clinical Trial?
Janssen Research & Development, LLC
Lead Sponsor
Joaquin Duato
Janssen Research & Development, LLC
Chief Executive Officer since 2022
MBA from ESADE, Master of International Management from Thunderbird School of Global Management
Dr. Jijo James, MD
Janssen Research & Development, LLC
Chief Medical Officer since 2014
MD from St. Johns Medical College, MPH from Columbia University